Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Lingzhi Anshen oral liquid for post-COVID-19 convalescent patients
ChiCTR2400091481Phase 4Completed
- Sponsor
- Taizhou Enze Medical Center
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of Fufang Lingzhi Anshen Oral Liquid in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Taizhou Enze Medical Center. Primary endpoints: Fatigue improvement and Sleep quality. Started Oct 2024; status: completed.
02
Drugs
Fufang Lingzhi Anshen Oral Liquid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2400091481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091481.